The Impact of IP-Related Anti-competitive Agreements on Market Dynamics

Intellectual property rights and competition law appear to pull in opposite directions – one grants exclusivity, the other demands openness. But this tension becomes most legally significant when IP-related agreements are used not just to protect innovation, but to foreclose it. Patent pooling arrangements, exclusive licensing deals, grant-back clauses, and standard essential patent licensing are all legitimate commercial tools. Yet each of them carries a real risk of tipping from lawful protection into anti-competitive conduct. Understanding where that line falls – and how Indian law draws it – is essential for anyone working at the intersection of IP and competition law.

The foundational tension: IP rights vs. market competition 🔗

IP law and competition law share a common end goal – consumer welfare and efficient markets – but take very different routes. IP law rewards innovation by granting creators a temporary monopoly: a patent holder, for instance, enjoys exclusive rights over their invention for 20 years from the filing date under the Patents Act, 1970. Competition law, on the other hand, intervenes when market power – including that derived from IP rights – is used to distort competition.

The Competition Act, 2002 is India’s primary framework for regulating anti-competitive conduct. Section 3 prohibits agreements that cause an appreciable adverse effect on competition (AAEC) in India. Section 4 addresses abuse of dominant position. Crucially, Section 3(5) carves out a conditional safe harbour for IP holders – allowing them to impose reasonable conditions to protect their rights. But this exemption is not unlimited. As competition law practitioners note, any such condition still has to pass the scrutiny of Section 3(5) to qualify for the exemption, and the exemption itself does not extend to abuse of dominance under Section 4.

Anti-competitive IP agreements: key types and concerns 🔗

Patent pooling: collaborative efficiency or cartel cover? 🔗

A patent pool is an arrangement where two or more patent holders collectively license their patents – either to each other or to third parties – under a single agreement. On paper, this streamlines access to multiple technologies and reduces transaction costs. In sectors like healthcare, the WHO has recognised patent pools as an effective tool to provide affordable access to life-saving drugs. The Medicines Patent Pool (MPP), established by Unitaid, is a well-known example that enables generic manufacturers to produce medicines for HIV, malaria, and COVID-19 in lower-income countries.

However, the competition law concerns are real. Pools of substitute technologies – where competing technologies are bundled together – can function as price-fixing arrangements, which are presumed anti-competitive under Section 3 of the Competition Act. The concern intensifies when a pool includes non-essential patents alongside essential ones, forcing licensees to pay for technology they do not actually need. This practice, known as bundling, is treated as an anti-competitive restraint. Additionally, collective control over key patents can reduce incentives to innovate further, as firms may become complacent rather than continuing to push technological boundaries.

India’s Patents Act does not explicitly mention patent pooling. However, Sections 68 and 69 of the Patents Act, 1970 govern the assignment and licensing of patents (requiring written agreements and registration), while Section 140 restricts conditions that cannot be included in a licence. Where a voluntary licence cannot be secured, Section 84 permits compulsory licensing – a mechanism that can also facilitate the formation of a patent pool.

Exclusive licensing arrangements 🔗

An exclusive licence grants a single licensee the right to use a patented technology, cutting out all other potential users. While this can incentivise a licensee to invest heavily in commercialising the technology, it also raises significant competition concerns. Exclusive licensing or grant-back clauses may reduce innovation or eliminate potential market entrants, particularly when the licensor is dominant and the technology is essential to operating in a market.

Section 3(4) of the Competition Act expressly prohibits several vertical restraints including exclusive supply agreements and exclusive distribution arrangements if they cause AAEC. The CCI’s own note to the OECD confirms that the Section 3(5) safe harbour for IPR protection is not a blanket exemption – conditions imposed must be reasonable and proportionate to protecting the IP right in question. An exclusive licence that goes beyond what is necessary for that protection can, and does, attract antitrust scrutiny.

Grant-back clauses and no-challenge clauses 🔗

Some licensing agreements contain a grant-back clause, requiring the licensee to assign or license back to the original IP holder any improvements they develop on the licensed technology. This can deter licensees from innovating, since they know they will not fully own what they create. Even more problematic are no-challenge clauses, which bar a licensee from questioning the validity of the IP right they are licensed under. Such clauses, discussed in the European Commission’s Technology Transfer Guidelines, carry a high potential to restrict competition and require case-by-case scrutiny. A patent whose validity cannot be challenged is a patent that could remain a barrier to competition even if it should never have been granted.

Pay-for-delay agreements in the pharmaceutical sector 🔗

Pay-for-delay agreements – sometimes called reverse payment settlements – are particularly prevalent in the pharmaceutical industry. Here, an originator pharmaceutical company pays a generic manufacturer to acknowledge the patent and agree not to bring a competing generic drug to market for a defined period. These arrangements are a form of patent dispute settlement but operate as a form of market division – keeping cheaper alternatives off shelves and harming consumers.

Standard essential patents and FRAND licensing: the Ericsson-Micromax saga 🔗

Standard Essential Patents (SEPs) are patents that must be used to implement an industry standard – such as 2G, 3G, or 4G communication protocols. When a technology becomes embedded in a standard, its patent holder acquires enormous market power, because there is no way to comply with the standard without using the patent. Standard-setting organisations typically require SEP holders to commit to licensing on FRAND (Fair, Reasonable and Non-Discriminatory) terms to prevent exploitation of this leverage.

India’s most significant SEP dispute illustrates precisely what goes wrong when FRAND obligations are not honoured. In 2013, Micromax Informatics Ltd. filed a complaint before the CCI against Ericsson, the dominant holder of SEPs for 2G and 3G wireless communication standards. Micromax alleged that Ericsson was demanding excessive royalties calculated on the basis of the entire selling price of the handset – rather than the value of the specific patented technology used in the chipset – and was also insisting on non-disclosure agreements as a condition of licensing.

The CCI found this approach prima facie discriminatory, noting that the royalties charged had no rational link to the patented product and were contrary to what FRAND obligations require of an SEP holder. Ericsson challenged the CCI’s jurisdiction in the Delhi High Court, arguing that patent-related matters fall exclusively under the Patents Act. The Delhi High Court rejected this challenge, holding that Competition Act and the Patents Act offer different remedies and are complementary – the Patents Act provides compulsory licensing as a remedy in personam, while the Competition Act provides broader remedies including penalties and cease-and-desist orders in rem. The Delhi High Court upheld the CCI’s jurisdiction to investigate abuse of dominance by an SEP holder.

This case exposed significant gaps in India’s regulatory framework for SEP disputes. The absence of clear FRAND guidelines led to lengthy parallel litigation before both the CCI and the Delhi High Court, ultimately dragging on from 2013 to 2019. It also highlighted the problem of royalty stacking – where a manufacturer implementing multiple standards must pay separate royalties to multiple SEP holders, creating cumulative costs that can make market entry prohibitive for smaller players and startups.

The Monsanto Bt cotton case: exclusive licensing and market dominance 🔗

The anti-competitive potential of exclusive licensing was also starkly demonstrated in the Monsanto Bt cotton technology case. The CCI found that Monsanto’s sub-licensing agreements for Bt cotton technology appeared to cause appreciable adverse effect on competition in the Bt cotton technology market. In particular, the termination conditions in Monsanto’s sub-licences were found to be excessively harsh and not proportionate to what was necessary for protecting the underlying IP rights. The case involved exclusive supply agreements and refusals to deal with Indian seed manufacturers – conduct that fell squarely within the prohibitions of Sections 3(4)(b) and 3(4)(d) of the Competition Act.

Monsanto’s jurisdictional challenge – arguing that the CCI had no power to interfere with rights exercised under the Patents Act – was rejected by the Delhi High Court. Indian courts have consistently held that there is no “irreconcilable conflict” between the Competition Act and the Patents Act, confirming that competition law operates alongside IP law rather than in deference to it.

How the Competition Act scrutinises IP agreements: the AAEC analysis 🔗

When the CCI examines whether an IP-related agreement causes AAEC, it looks at the factors listed in Section 19(3) of the Competition Act. These include whether the agreement creates barriers to entry, forecloses competition by blocking rivals from the market, leads to market division, or restricts technological or scientific development. Section 3(4) of the Act expressly prohibits tie-in arrangements, exclusive supply agreements, and exclusive distribution arrangements when they have anti-competitive effects. The CCI has made clear that the Section 3(5) exemption does not protect conditions that go beyond what is reasonably necessary for IP protection.

The overall framework requires a case-by-case analysis. Not every patent pool is anti-competitive; not every exclusive licence harms competition. What matters is the net effect on market dynamics – whether the agreement’s restrictive aspects outweigh its legitimate benefits in protecting and incentivising IP.

The broader policy challenge for India 🔗

India’s technology and pharmaceutical sectors are both deeply affected by how IP-related agreements are regulated. India’s compulsory licensing provisions under the Patents Act can create uncertainties for R&D-intensive companies, while the CCI’s growing assertiveness in scrutinising licensing terms signals that IP rights cannot be weaponised to achieve market dominance beyond what the law permits. The Raghavan Committee’s report on competition law noted the dichotomy between IPR policy, which “endangers competition,” and competition policy, which “engenders competition” – a tension that requires ongoing regulatory calibration rather than a permanent resolution in favour of either regime.

What both regimes agree on is that the monopoly granted by an IP right is a means to an end – the end being innovation and consumer welfare – and not an end in itself. When IP agreements are structured in ways that use exclusivity as a tool to eliminate rivals, fix prices, divide markets, or erect permanent entry barriers, they cross from IP protection into competition law violation.

What do you think? Should India establish a dedicated regulatory framework or tribunal specifically to handle SEP and FRAND disputes, rather than leaving them to general competition and civil courts? And when a patent pool includes both essential and non-essential patents, at what point does the bundling of those rights cross from efficient licensing into an anti-competitive restraint?

References

1. https://ipindia.gov.in/writereaddata/Portal/IPOAct/1_31_1_patent-act-1970-11march2015.pdf
2. https://www.indiacode.nic.in/handle/123456789/2010
3. https://blog.ipleaders.in/interplay-competition-law-ipr/
4. https://ssrana.in/articles/competition-law-regime-and-patent-pooling/
5. https://cbcl.nliu.ac.in/competition-law/the-dichotomy-between-competition-law-and-ipr/
6. https://ksandk.com/competition/balancing-ip-rights-and-competition-law-in-india/
7. https://one.oecd.org/document/DAF/COMP/WD(2019)4/en/pdf
8. https://legalblogs.wolterskluwer.com/competition-blog/ericsson-v-micromax-a-kick-start-to-the-sep-frand-antitrust-jurisprudence-in-india/
9. https://indiankanoon.org/doc/164770226/
10. https://nliulawreview.nliu.ac.in/blog/frand-theft-auto-navigating-standard-essential-patents-in-india/
11. https://academic.oup.com/antitrust/article/5/2/299/3788021
12. https://www.saikrishnaassociates.com/balancing-act-competition-law-and-intellectual-property-rights-in-india/
13. https://asiaiplaw.com/article/indias-ip-and-competition-laws-complementary-or-conflicting